

**Non-obese diabetic (NOD) mice congenic for a targeted deletion of 12/15-lipoxygenase are protected from autoimmune diabetes.**

Marcia McDuffie, MD; University of Virginia  
Nelly A. Maybee, MD; University of Virginia  
Susanna R. Keller, MD; University of Virginia  
Brian K. Stevens; University of Virginia  
James C. Garmey, MS; University of Virginia  
Margaret A. Morris, Ph.D; University of Virginia  
Elizabeth Kropf, BS; University of Virginia  
Claudia Rival, Ph.D; University of Virginia  
Kaiwen Ma, MD, Ph.D; University of Virginia  
Jeffrey D. Carter, BA; University of Virginia  
Sarah A. Tersey, Ph.D; University of Virginia  
Craig S. Nunemaker, Ph.D; University of Virginia  
Jerry L. Nadler, MD; University of Virginia

**Running Title:** Protection from diabetes by deletion of 12/15 lipoxygenase

**Corresponding author:**

Jerry L. Nadler, MD  
University of Virginia  
P.O. Box 801405  
Charlottesville, VA 22908

Received for publication 19 June 2007 and accepted in revised form 9 October 2007.

## ABSTRACT

**Objective:** 12/15-lipoxygenase (12/15-LO), one of a family of fatty acid oxidoreductase enzymes, reacts with polyenoic fatty acids to produce pro-inflammatory lipids. 12/15-LO is expressed in macrophages and pancreatic  $\beta$ -cells. It enhances interleukin 12 production by macrophages, and several of its products induce apoptosis of  $\beta$  cells at nanomolar concentrations *in vitro*. We had previously demonstrated a role for 12/15-LO in  $\beta$ -cell damage in the streptozotocin model of diabetes. Since the gene encoding 12/15-LO (gene designation: *Alox15*) lies within the *Idd4* diabetes susceptibility interval in NOD mice, we hypothesized that 12/15-LO is also a key regulator of diabetes susceptibility in the NOD mouse.

**Research Design and Methods:** We developed NOD mice carrying an inactivated 12/15-LO locus (NOD-*Alox15*<sup>null</sup>) using a 'speed congenic' protocol and the mice were monitored for development of insulinitis and diabetes.

**Results:** NOD mice deficient in 12/15-LO develop diabetes at a markedly reduced rate compared to NOD mice (2.5% vs. >60% in females by 30 weeks). Non-diabetic female NOD-*Alox15*<sup>null</sup> mice demonstrate improved glucose tolerance, as well as significantly reduced severity of insulinitis and improved  $\beta$ -cell mass, when compared to age-matched non-diabetic NOD females. Disease resistance is associated with decreased numbers of islet-infiltrating activated macrophages at 4 weeks of age in NOD-*Alox15*<sup>null</sup> mice, preceding the development of insulinitis. Subsequently, islet-associated infiltrates are characterized by decreased numbers of CD4<sup>+</sup> T cells and increased Foxp3<sup>+</sup> cells.

**Conclusions:** These results suggest an important role for 12/15-LO in conferring susceptibility to autoimmune diabetes in NOD mice through its effects on macrophage recruitment or activation.

The non-obese diabetic (NOD) mouse is a well established animal model for Type 1 diabetes mellitus (1). Genetic susceptibility in NOD mice has been mapped to more than 30 genetic regions, currently designated “insulin-dependent diabetes” (*Idd*) loci (2). Susceptibility determinants on mouse chromosome 11 were first recognized by linkage to the microsatellite *D11Nds1* after outcross of NOD to the C57BL/10 strain, with C57BL/10 alleles decreasing the severity of insulinitis in young mice. Linkage to this region of chromosome 11, designated *Idd4* (3), was confirmed in a cross with the NOD-related NOR strain, which is a genetic mosaic of NOD with two non-diabetes-prone mouse strains: C57BL/6 and DBA/2. In this cross DBA/2-derived alleles on chromosome 11 decreased the incidence of diabetes after administration of cyclophosphamide (4). Subsequently, congenic strains generated from crosses with C57L (5,6), C57BL/6 (7), and NOR (4,8) mice demonstrated that the initial mapping results were produced by a cluster of susceptibility loci, now designated *Idd4.1*, *Idd4.2*, and *Idd4.3* (also designated *Idd4a*). Functional polymorphisms of both *Stat5b* and *Il12b* (encoding the 40 kD chain of interleukin 12, IL-12p40), located at the telomeric and centromeric ends of chromosome 11, respectively, have been identified in NOD mice (9-11) and may have contributed to evidence for linkage on chromosome 11 in the initial C57BL/10 cross. To date, however, no strong candidate genes for the *Idd4.1-4.3* loci, mapped to mid-chromosome, have been both identified and validated.

Based on its known functions and its genomic location, the 12/15-LO locus (*Alox15*) represents an excellent candidate for *Idd4.1*. Also known as “leukocyte 12-lipoxygenase”, this enzyme catalyzes the oxygenation of polyenoic fatty acids (including arachidonic acid and linoleic acid) to form lipid inflammatory mediators, such as 12-hydroperoxyeicosatetraenoic acid (12-HPETE) and 13-(S)-hydroperoxy-9Z,11E-octadecadienoic acid (13-HPODE). Although 12/15-LO is expressed in other cell types, high levels of mRNA, protein, and enzyme activity are reported in macrophages and pancreatic  $\beta$ -cells from both mice and humans (12,13). 12-HPETE is toxic at physiological levels to  $\beta$ -cells, where it is also converted to

a more stable metabolite 12-hydroxyeicosatetraenoic acid (12-HETE) by glutathione peroxidase (GPX) (14). 12-HETE is also directly toxic to  $\beta$ -cells and human islets, markedly decreasing insulin secretory function and increasing  $\beta$ -cell death (13). 12-HETE can be further metabolized to 12-HETrE, which acts as a pro-inflammatory agent and co-localizes with insulin in  $\beta$ -cells (15). 12-HETE can activate NF $\kappa$ B, p38, stress-activated protein kinase JNK1/2 and p21-activated kinases, all possible mediators of cytokine induced  $\beta$ -cell damage (13). It is reasonable to postulate, therefore, the 12/15-LO activity may enhance the susceptibility of pancreatic  $\beta$ -cells to cytotoxic insults.

In addition to its activities in pancreatic  $\beta$ -cells, 12/15-LO regulates pro-inflammatory activity of myeloid cells, including macrophages. Macrophages are present in large numbers adjacent to the islets of young, pre-diabetic NOD mice before the onset of substantial T cell infiltration (16-21), and specific defects in macrophage development and function have been repeatedly demonstrated in NOD mice (6,22-30). Products of 12/15-LO activity stimulate expression of macrophage-derived cytokines, such as IL-12 (31), and these cytokines can up-regulate 12/15-LO expression itself in a positive feedback loop, suggesting that it may also participate in  $\beta$ -cell destruction by enhancing the pro-inflammatory activity of islet-associated macrophages (32-34). A null mutation in mice (*Alox15<sup>tm1fun</sup>*) reduces the atherogenic effects of loss of ApoE, presumably via demonstrated decreases in production of the arachidonic acid metabolites 12-HETE and 15-HETE in circulating macrophages (35). We have also demonstrated that mice homozygous for 12/15-LO mutation are markedly less susceptible to low-dose-streptozotocin-induced diabetes than wild-type littermates (36). Thus, 12/15-LO may play an important role in enhancing tissue-specific inflammation in multiple settings *in vivo*.

In order to test the possibility that 12/15-LO may regulate disease susceptibility in the spontaneous diabetes of NOD mice, we generated NOD mice congenic for the *Alox15<sup>tm1fun</sup>* null mutation. We show that these mice are profoundly resistant to the

development of diabetes. The decreased incidence of overt diabetes is associated with markedly diminished insulinitis, as well as preservation of islet mass and function. Preceding these late events, we find that loss of 12/15-LO activity prevents peri-islet accumulation of activated macrophages that are routinely seen in young NOD mice and leads to a significant decrease in CD4<sup>+</sup> T cell infiltration into islets, along with increased numbers of Foxp3<sup>+</sup> cells, in mature animals. These findings suggest that 12/15-LO is a major regulator of initiation and progression of insulinitis in the NOD mouse through its effects on the accumulation of macrophages in islet tissue and, further, that blockade of 12/15-LO activity may provide a novel strategy for prevention and treatment of Type 1 diabetes.

## METHODS

**Mice.** A B6.129S2-*Alox15*<sup>tm1Fun</sup> male mouse, kindly provided by Dr. Colin Funk (37), was mated with an NOD female, followed by successive backcrosses to NOD males in a “speed congenic” strategy, using mapped polymorphic microsatellites for genotypic selection (panel available upon request to MM). The NOD mice used in this study were obtained from a breeding nucleus at the Barbara Davis Center for Childhood Diabetes (Denver, CO) and have been propagated at the University of Virginia by brother-sister mating since 1993. All mice are bred and maintained in a pathogen-free colony in the Center for Comparative Medicine under protocols approved by the institutional Animal Care and Use Committee using AALAAC guidelines.

**Genotyping.** High quality genomic DNA was prepared from tail or liver by standard methods. For all microsatellite analysis, oligonucleotide pairs for mapped loci were used to amplify sequence-specific genomic DNA using a modification of published methods (38). For whole genome scans, fluorochrome-labeled primers were synthesized using oligonucleotide sequences from the public domain (38). Fluor-labeled amplicons were pooled into multiplex sets and analyzed on an automated ABI sequencer using Genescan<sup>TM</sup> and Genotyper<sup>TM</sup> software (Applied Biosystems, Foster City, CA). For analysis of individual loci, PCR products amplified with unlabeled primers were separated on a 4% agarose gel and visualized

with ethidium bromide. The mutant *Alox15* allele was genotyped during backcross breeding using a standard set of primers recognizing a retained neomycin-resistance cassette, using published primer sequences and protocol (IMR0013: 5'-CTTGGGTGGAGAGGCTATTC -3' and IMR0014:5'-AGGTGAGATGACAGGAGATC-3'; protocol available at the following URL: <http://www.jax.org/imr/touchdown.html>).

For allele-specific genotyping of *Alox15*, PCR was performed using the following primers: CDF 141: 5'-ATC GCC TTC TTG ACG AGT TC, CDF 233: 5'-TCC TGA ACA GGC CTT GAG AG, and CDF 234: 5'-GAG GGC ACT GGT GAG CAG A (37,39). PCR was performed for 35 cycles using an annealing temperature of 65° C. Products were separated on 1% agarose gel and visualized with ethidium bromide. The mutant allele yields a 700 base-pair (bp) fragment indicating disruption of *Alox15*, while a 350 bp fragment is generated from the wild-type allele.

**Determination of disease status.** Mice at risk for development of diabetes were screened for polyuria and morning glycosuria beginning at 10 weeks of age. Individuals with urine glucose concentrations >500 mg/dL twice at 24-hour intervals received 0.5 units per day of human Ultralente insulin. After 7 consecutive days of insulin requirement, diabetes was confirmed with a blood glucose measurement using an UltraTouch glucometer (Lifescan, Inc., Milpitas, CA). All mice that required insulin for 7 consecutive days had blood glucose concentrations >300 mg/dL. Mice exhibiting no glycosuria by 210 days of age were euthanized for pancreatic histology after confirmation of normoglycemia (morning blood glucose <140 mg/dL).

**Macrophage isolation and detection of 12/15 LO by immunoblotting and real time PCR.** Male NOD-*Alox15*<sup>hull</sup> and NOD mice (6-8 months old) were injected with sterile 4% thioglycollate; after 72 hours, cells were pelleted from ascites, washed with RPMI-1640 medium containing 10% FBS and 100u/ml of penicillin/streptomycin containing EDTA, and cultured for 3 hours at 37°C in 5% CO<sub>2</sub>. Non-adherent cells were removed by multiple washes with Hank's buffered

saline. Adherent cells were washed with 10% non-heated FBS and incubated for 2 days with a second wash to remove non-adherent cells after 24 hours. Protein was isolated using CelLytic M Cell Lysis Reagent (Sigma, St. Louis, MO).

For quantitation of 12/15-LO protein, cell lysates from two mice from each strain were pooled and proteins separated by electrophoresis on a 10% polyacrylimide gel (50ug protein per lane). Actin was used as loading control. Primary antibodies: 12/15-LO polyclonal rabbit, affinity purified A2460, BLD B&4 (used at 1:2500; synthesized in the Nadler laboratory). Polyclonal rabbit anti-mouse actin (1:2500; Santa Cruz Biotechnology, Santa Cruz, CA) was used as loading control. Secondary antibodies: anti-rabbit IgG-HRP (1:5000; Santa Cruz).

RNA was isolated from 4% thioglycolate stimulated peritoneal macrophages according to Qiagen RNeasy Mini Kit instructions (including an optional DNase step) right after the completion of incubation period. PCR was performed on Stratagene MX3000P™ with MxPro™ Version 3 software, using the following 12/15-LO primers: forward, 5'-CTCTCAAGGCCTGTTTCAGGA-3'; reverse, 5'-GTCCATTGTCCCCAGAACCT-3', with annealing temperature 62°C and extension temperature of 72°C and final extension of 81°C (40). The concentration of  $\beta$ -actin (forward, 5'-AGAGGGAAATCGTGCGTGAC-3'; reverse, 5'-CAATAGTGATGACCTGGCCGT-3', with annealing temperature of 62°C) was no different between the samples from the two strains.

**Metabolic testing.** For testing glucose tolerance, mice were fasted overnight and then injected intraperitoneally with glucose (2g/kg). Blood glucose measurements were performed with a UltraTouch glucometer using blood samples taken from cut tail tips at baseline and at 10, 20, 30, 60, 90 and 120 minutes after the injection of glucose. Fasting plasma insulin was measured in blood obtained from tail veins after an overnight fast, using a commercial insulin radioimmune assay (Catalog No. SRI-13K, Linco Research Inc., St. Charles, MI). Plasma was also collected during IPGTT at baseline, 10, and

30 minutes for insulin measurements using Ultrasensitive Rat/Mouse Insulin ELISA (Crystal Chem Inc., Downers Grove, IL). HOMA (Homeostasis Model Assessment) was calculated using the following formula: [fasting insulin ( $\mu$ U/ml) x fasting blood glucose (mM)]/22.5.

**Histological scoring for insulinitis.** Whole pancreas was spread onto plastic cassettes and fixed for 24 hours in 10% buffered formalin prior to automated processing and embedding in paraffin. Consecutive 4  $\mu$ M sections (3 per slide) were stained with aldehyde fuchsin and hematoxylin. A single score, indicating average severity of insulinitis, was given for each mouse based on evaluation of all islets identified by morphology, using the following scale: 0, no infiltrate; 1, polar infiltrate only; 2, infiltrating cells extending around islet to >50% of its circumference without invasion; 3, invasive insulinitis. A  $\beta$ -cell score was determined as a product of the residual total islet mass, estimated as a fraction of that in age- and sex-matched NOD.scid control mice (0.0-1.0) multiplied by the average percentage of aldehyde fuchsin-positive cells per islet relative to control (0-100%). Adjunct perivascular and periductular infiltrates, indicative of total pancreatic inflammation, were also compared using a score of 0 (no evidence of mononuclear cell infiltrate) to 3 (extensive infiltrates associated with pancreatic ducts and blood vessels, independent of local islet tissue, and characterized by displacement of exocrine tissue as well as engorgement of lymphatics) (41).

**Immunofluorescence and immunohistochemistry.** Five-micron sections from flash-frozen pancreas were fixed in a 1:1 mixture of 100% ethanol and acetone, followed by blocking of endogenous biotin. For CD4, sections were incubated in rabbit anti-insulin (1:25 in 2% goat serum; Santa Cruz), followed by amplification with a biotinylated Goat-anti-Rabbit antibody (1:200; Vector Laboratories, Burlingame, CA) and Texas Red-labeled Neutralite-Avidin (1:300; SouthernBiotech, Birmingham, AL) or with FITC-labeled anti-CD4 (1:150; BD Biosciences, San Jose, CA) amplified using the Tyramide FITC amplification system (Perkin Elmer, Waltham, MA). In order to

visualize islet-associated Foxp3, sections were stained for insulin using rabbit anti-insulin as above, followed by Cy2-labeled Goat-anti-Rabbit (1:50, Jackson ImmunoResearch, West Grove, PA). Sections were then incubated with biotin anti-mouse Foxp3 (1:100, eBiosciences, San Diego, CA), followed by amplification with the Tyramide Biotin amplification system (Perkin Elmer) coupled with Texas Red-labeled Neutralite-Avidin. All sections were stained with Hoechst Dye (5mg/ml; Invitrogen, Carlsbad, CA) to visualize nuclei. Stained sections were viewed and photographed on an Olympus BX51WI fluorescence microscope (Olympus, Tokyo, Japan). Excitation light was supplied to the sections by a xenon burner through a filter wheel containing DAPI, FITC, and TRITC filters (Sutter Instrument Company, Novato, CA). Images were taken using a Hamamatsu ORCA-ER monochrome CCD camera (Hamamatsu Photonics, Japan). Data were acquired with IPLab software version 4.0 (Scanalytics, Rockville, MD), and analyzed in NIH Image J (NIH, Bethesda, MD).

For Mac-2 staining, pancreata from 4 week old NOD and NOD-*Alox15<sup>null</sup>* mice were fixed with 4% paraformaldehyde by heart perfusion. Tissues were dissected and incubated an additional 1 hour in 4% paraformaldehyde, dehydrated in 70% ethanol and embedded in paraffin. Non-specific background was eliminated by 30-minute incubation in methanol with 0.5% hydrogen peroxide, followed by blocking for one hour in PBS containing 10% normal rabbit serum (NRS) and avidin/biotin blocking reagent (Vector Laboratories). Activated macrophages were identified using rat anti-mouse Mac-2 (1:20000, Accurate Chemical, Westbury, NY), followed by biotinylated anti-rat (mouse adsorbed) IgG (1:200, Vector Laboratories) and Vecstatin Elite® (Vector Laboratories) avidin-biotin-horseradish peroxidase reagent. Bound antibody complexes were visualized with diaminobenzidine hydrochloride in 0.02% hydrogen peroxide. Negative controls were prepared by substituting rabbit IgG for the primary antibody. Slides were scored in blind fashion, using the following criteria: 0, no macrophage staining; 0.5, some staining in islet periphery; 1, one to three macrophages inside islet; 2, four or more macrophages; 3, infiltration of >10% of islet surface.

**Statistical analysis.** Survival comparisons were analyzed by Log-rank test using MedCalc for Windows®, version 9.2.1.0. Results from glucose tolerance tests were compared using a 2-way ANOVA to compare blood glucose differences with respect to factors of time and mouse strain. Insulin levels during a GTT were compared using an unpaired, one-tailed t-test. Histological scores were compared using an unpaired, two-tailed t-test.

## RESULTS

**Generation of congenic NOD-B6;129S2-*Alox15<sup>tm1fun</sup>* mice.** A single founder B6;129S2-*Alox15<sup>tm1Fun</sup>* male homozygote (~13% 129S2) (37) was mated to NOD females. Using a panel of 106 informative microsatellites, covering all chromosomes except Y, breeding females were selected for minimal residual donor genome during 4 successive generations of backcross to NOD males. Selection for the primary *Alox15* mutation was made using a retained neomycin-resistance cassette. In order to limit the flanking non-NOD alleles, mice from one additional backcross generation ( $N=39$ ) were selected for a minimal congenic interval, followed by intercross with further selection for flanking microsatellite loci ( $N=86$ ). The final line carries a non-NOD donor interval, including undefined regions, extending from *D11Mit177* to *D11Mit245* (65.0 to 76.7 Mb; NCBI, build m36; Fig. 1A). It overlaps the intervals defining *Idd4.1* in the C57BL/6 and NOR congenic strains (Figure 1B:I-III), but carries NOD alleles at *I12b* and *Stat5b* (Figure 1A) as well as *Idd4.3* (6) (Figure 1B:IV). *Alox15* itself clearly resides in the *Idd4.1* genetic interval and can be considered a regional candidate gene for *Idd4.1*. The remainder of the non-NOD interval in the final NOD-*Alox15<sup>null</sup>* congenic strain, including the entire *Idd4.1* interval, is derived from the 129S2 genetic background.

### **Diabetes incidence in NOD-*Alox15<sup>null</sup>* mice.**

The cumulative incidence of diabetes in this congenic line is markedly decreased from that in contemporary cohorts of NOD mice (Figure 2 A-B), with only 1 of 40 female NOD-*Alox15<sup>null</sup>* homozygotes, and 0 of 33 males, becoming diabetic by 7 months of age ( $p < 0.0001$  and  $< 0.002$  for females and males, respectively, by Log-rank test). For females, the hazard ratio for diabetes is  $< 0.00005$

(95% confidence interval: 0.0137 to 0.1095). This contrasts with a published cumulative incidence of diabetes of 15% (3 of 20) in female NOD.B6/*lidd4a* mice (carrying the entire *lidd4.1-4.2* interval from C57BL/6 mice; Figure 1B/II; (7) and 60% (21 of 35) in female NOD.Nor-*lidd4* (long) mice carrying a protective interval from the NOR strain (42).

**Absence of *Alox15* gene expression in NOD-*Alox15*<sup>null</sup> macrophages.** We confirmed the absence of 12/15-LO with both RT-PCR and immunoblotting in macrophages from thioglycolate-elicited peritoneal exudates. As expected, we found high levels of 12/15-LO protein in cells from NOD mice, while it is undetectable NOD-*Alox15*<sup>null</sup>. Similarly, we found no evidence of residual mRNA expression using primers spanning intron 2; Figure 2D shows a 750-fold difference in 12/15-LO mRNA abundance between the two strains.

**Glucose Tolerance Test.** 12/15-LO is expressed at high levels in pancreatic islets, but its normal role in this tissue is unknown. In order to determine whether pancreatic  $\beta$ -cells were less responsive in the absence of 12/15-LO activity, we challenged 8-month-old non-diabetic female NOD and NOD-*Alox15*<sup>null</sup> mice with an intraperitoneal glucose tolerance test (IPGTT). As is shown in Figure 3, NOD-*Alox15*<sup>null</sup> mice cleared glucose more efficiently than NOD mice. Blood glucose values over the entire time course of the test were lower in the NOD-*Alox15*<sup>null</sup> mice compared to non-diabetic NOD controls ( $p < 0.0001$  by two-way ANOVA). This result suggested that the NOD-*Alox15*<sup>null</sup> mice were either more insulin-sensitive or maintained better  $\beta$ -cell function than NOD mice. Mean fasting blood glucose and insulin levels were similar in the NOD-*Alox15*<sup>null</sup> and in the NOD controls (Table 1), resulting in a similar HOMA index (a measure of insulin sensitivity) between the two strains. However, while insulin levels peaked at 10 minutes in both groups, peak insulin concentration was significantly higher in NOD-*Alox15*<sup>null</sup> mice than in the NOD group (0.87ng/ml +/- 0.117 vs 0.39ng/ml +/- 0.194,  $P = 0.04$ ), consistent with better preservation of islet mass and function in older mice from the congenic strain.

**Severity of insulinitis in NOD-*Alox15*<sup>null</sup> mice.**

As expected, based on improved insulin production in NOD-*Alox15*<sup>null</sup> mice after IPGTT, pancreatic histology in non-diabetic NOD-*Alox15*<sup>null</sup> females at 30 weeks of age showed a marked reduction in both invasive insulinitis and  $\beta$ -cell damage compared to age-matched non-diabetic NOD females. A representative pancreatic section from an NOD-*Alox15*<sup>null</sup> female mouse is shown in Figure 4A and demonstrates significant perivascular/periductular mononuclear cell inflammation, but no evidence of invasive insulinitis. This contrasts with a representative section from an age-matched non-diabetic female NOD mouse, showing a heavily infiltrated islet with loss of  $\beta$ -cell insulin granules (Figure 4B). Islet-associated infiltrates in NOD-*Alox15*<sup>null</sup> mice were almost exclusively limited to polar accumulations of mononuclear cells (average score per pancreas  $< 1.0$ , on a scale of 0-3), while islets from surviving non-diabetic NOD females at 30 weeks showed invasive insulinitis (average score  $> 2.5$ ;  $P < 0.001$ ; Table 2).

Perivascular/periductular inflammation was seen in both strains at this age, but the extent of these infiltrates was significantly decreased in congenic mice (Table 2). Both the residual islet mass and the intensity/extent of aldehyde fuchsin-positive islet cells were well-preserved in NOD-*Alox15*<sup>null</sup> females relative to age-matched non-diabetic NOD females, producing a significantly increased score for  $\beta$ -cell preservation in the NOD-*Alox15*<sup>null</sup> mice ( $P < 0.001$ ).

**Recruitment of CD4<sup>+</sup> T cells and Foxp3<sup>+</sup> regulatory T cells in NOD-*Alox15*<sup>null</sup> mice.**

CD4<sup>+</sup> cells were also markedly decreased in pancreatic sections from NOD-*Alox15*<sup>null</sup> mice. At 9.5 weeks, CD4 staining was much more prevalent in NOD mice (Figure 5A) than NOD-*Alox15*<sup>null</sup> mice (Figure 5B). By ~30 weeks of age, we observed accumulations of CD4<sup>+</sup> T cells near islets from both NOD and NOD-*Alox15*<sup>null</sup> mice (Figures 5C and 5D). However, many more islets were observed in sections from NOD-*Alox15*<sup>null</sup> mice (66 islets from 2 NOD-*Alox15*<sup>null</sup> mice versus 16 in 2 NOD mice), and a larger percentage of these islets showed no signs of insulinitis (~50% of NOD-*Alox15*<sup>null</sup> islets versus ~10% of NOD islets). Since increased development and accumulation of regulatory T cells might

provide a mechanism for decreasing both the extent and destructiveness of islet-associated inflammation in NOD-*Alox15<sup>null</sup>* mice, we stained sections from 30-week-old mice for Foxp3. Foxp3 is a transcription factor involved in the development of regulatory T cells and is used as a marker for identifying these cells. As shown in Figure 5E, very little Foxp3 staining was typically observed among islets from NOD mice, whereas substantial numbers of Foxp3<sup>+</sup> cells were observed among NOD-*Alox15<sup>null</sup>* islets with signs of insulinitis (Figure 5F). Foxp3<sup>+</sup> cells were generally not observed in or near pancreatic islets in the absence of insulinitis in either strain (data not shown).

**Macrophage infiltration in 4-week-old NOD-*Alox15<sup>null</sup>* mice.** Early islet invasion by macrophages is a characteristic feature of disease process in NOD mice and precedes accumulation of lymphocytes (18). Since 12/15-LO has been shown to enhance macrophage activation, we postulated that a decrease in the presence of activated macrophages associated with pancreatic islets might be responsible for the reduced severity of insulinitis along with an increase in cells with apparent regulatory function in NOD-*Alox15<sup>null</sup>* mice. Pancreata from 4-week-old female mice, prior to the development of detectable pancreatic T cell infiltration in the NOD controls, were stained for the macrophage activation marker, Mac-2. Figure 6 shows representative examples of islets from the two strains, with brown staining signifying infiltration with activated macrophages. Using a blinded scoring system we found islet-associated Mac-2-positive macrophages in or around 36% of islets (20/56) from NOD-*Alox15<sup>null</sup>* mice, whereas 65% of NOD islets (62/96) were Mac-2-positive ( $P < 0.001$ ). This difference is also reflected in the mean Mac-2 score for each group: NOD: 0.833 +/- 0.075, NOD-*Alox15<sup>null</sup>*: 0.55 +/- 0.097,  $P=0.02$ ), indicating greater intra-islet accumulation of Mac-2-positive cells in pancreatic sections from NOD mice.

## DISCUSSION

Our previous studies had demonstrated that targeted deletion of 12/15-LO in mice with a largely C57BL/6 genetic background resulted in protection from streptozotocin-induced  $\beta$ -cell destruction (36). In this study, we show

that deletion of 12/15-LO activity via a congenic strategy is also associated with a decrease in autoimmune diabetes in NOD mice. This finding suggests that 12/15-LO may play a direct role in the development of diabetes in this strain.

As noted in the introduction, *Alox15* resides within a previously identified diabetes susceptibility locus, *Idd4.1*, on mouse chromosome 11. Danska and her colleagues have recently published an elegant and comprehensive analysis of gene expression in the *Idd4.1* interval using NOR.NOD-*Idd4* congenic mouse lines (42). In these mice, segments of NOD chromosome 11 near *Idd4.1* (Figure 1B/III) introduced an increase in spontaneous as well as cyclophosphamide-accelerated diabetes when they were bred onto the normally diabetes-resistant NOR genetic background, which itself is a complex mixture of DBA/2, C57BL/Ks, and NOD. Following demonstration that the *Idd4.1* interval carries alleles from the non-diabetes-prone DBA/2 strain in NOR mice, they used microarray expression analysis to identify regional genes with differential expression in NOR and NOD mouse bone-marrow-derived macrophages. Eleven of 52 regional genes were differentially expressed in these strains. Of these genes, the NOD and DBA/2 alleles of *Alox15* and the closely linked gene *Psm6*, encoding a proteasome component, were also shown to differ in both potential regulatory sequence and predicted amino acid sequence, suggesting that they should be considered the primary regional candidates for controlling diabetes susceptibility in NOR mice. Interestingly, however, comparative sequencing showed that the NOD and C57BL/6 *Alox15* alleles appear to be identical at the genomic level. This observation makes it unlikely that this locus is responsible for *Idd4* loci mapped using crosses with C57BL/6 mice studied by Delovitch and colleagues (7) (Figure 1B/II) or the original genetic mapping with C57BL/10 (6). Furthermore, *Alox15* mRNA is actually increased in disease-resistant NOR mice relative to the diabetes-prone congenic strains, suggesting that any differential effects of 12/15-LO in the NOR congenic strains operates by a different mechanism than that in our 12/15-LO-deficient strain.



All of the models generated to identify specific diabetes susceptibility loci on Chr 11, including ours, have used a congenic strategy because of the lack of NOD-derived embryonic stem cells that are competent for homologous recombination with germ-line transmission of induced mutations. The use of congenic mice inevitably imposes constraints on the interpretation of differences in complex phenotypes, such as autoimmune diabetes, because of the extended regions of allelic variation flanking the gene or locus of primary interest. Even with careful attention to generation of a pure NOD genetic background, it is clearly possible that non-NOD alleles of more than one gene in the interval flanking the target gene could modify the incidence of diabetes in a congenic strain. During our congenic derivation, we had initially isolated, and bred to homozygosity, a larger fragment from the donor strain that carried both 129S2 and B6 alleles within the 50 Mb interval bounded by *D11Mit84* (34.4 Mb, mNCBI 36) and *D11Mit33* (81.6 Mb). In these mice, 129S2 alleles extended from the centromeric end of the interval to a recombination point between *D11Mit320* and *D11Mit364* (70.8 and 72.0 Mb, respectively) with the remaining interval derived from the B6 strain. Homozygous *Alox15<sup>null</sup>* congenic mice carrying this longer interval had only a modest decrease in the incidence of diabetes (46% of 41 females observed to 30 weeks of age, compared to an incidence of 65% in a contemporary cohort of NOD female mice). A similar incidence was observed in a small group of mice homozygous for a shorter fragment consisting only of 129S2-derived alleles flanked by *D11Mit84* and *D11Mit364* (4 of 8 females). In both of these lines, disease incidence in congenic males was modestly decreased relative to that in NOD males (17% for congenic mice vs. 25% for NOD). Taken together with the markedly lower incidence observed in the final NOD-*Alox15<sup>null</sup>* line presented in this report, these results strongly suggest that a 129S2-derived susceptibility allele is present for at least one gene in the 30 Mb interval extending from *D11Mit84* to *D11Mit113*. However, we still cannot rule out the possibility that the disease resistance conferred by the smaller congenic interval is enhanced by non-NOD alleles at genes tightly linked but telomeric to *Alox15*.

One regional gene that might be postulated to complicate interpretation of disease susceptibility in our mice is the gene encoding the capsaicin receptor, *Trpv1* (73.0 Mb), which lies within the congenic interval in our strain (Figure 1A). *Trpv1* was recently shown to be polymorphic in NOD mice when compared with B6 (43). Destruction of capsaicin-sensitive neurons in NOD mice protected them from severe, invasive insulinitis and resulted in improved insulin sensitivity. Furthermore, replacement of the NOD *Trpv1* allele with that from the B6 strain using congenic NOD.B6-*Idd4* mice produced phenotypes similar to those seen in capsaicin-treated NOD mice, leading these investigators to suggest that this gene may be a good candidate for the *Idd4.1* locus mapped using crosses between these two strains.

Based on microsatellite mapping, the *Trpv1* allele present in our final NOD congenic strain is derived from the C57BL/6 mouse and, therefore, must be considered a potential confounding factor in these studies. However, there remains significant controversy about the relationship of *Trpv1* variants to the development of diabetes in NOD mice (44). While a decrease in insulinitis and diabetes was seen after capsaicin treatment of NOD mice, functional abnormalities in the treated mice were limited to demonstrations of insulin resistance and poor calcium flux in neurons. Attempts to link *Trpv1* variants directly to autoimmune diabetes using the NOD-*Idd4* mouse strains produced by Grattan *et al.* are complicated by the recent demonstration that these strains are contaminated by C57BL/6 alleles across the powerful *Idd5* interval on chromosome 1(45). Thus, direct evidence that *Trpv1* participates in protecting these mice from autoimmune diabetes is lacking. Dissection of our congenic interval by further recombination will be required to determine whether *Trpv1* may contribute to the striking diabetes resistance in our congenic strain. This effort will be complemented by analysis of disease susceptibility in NOD-*Idd4* mice lacking contaminating C57BL/6 alleles at the loci contributing to *Idd5* that are currently under construction at the Type 1 Diabetes Repository (E. H. Leiter, personal communication).

In order to begin to determine the mechanism(s) by which diabetes is prevented

in NOD-*Alox15*<sup>null</sup> congenic mice, we studied the role of several key immune cells involved in the infiltration of the pancreatic islets over the course of diabetes pathogenesis. Insulinitis in NOD mice is initiated by infiltration of antigen presenting cells, such as macrophages and dendritic cells (18). Our data show that 4-week-old female NOD-*Alox15*<sup>null</sup> mice carry markedly reduced macrophage numbers in and around the islets, compared to age-matched NOD female controls. The mechanism for this reduction in islet-associated macrophages is not clear. However, accumulating evidence suggests that the 12/15-LO product, 12(S)-HETE, can up-regulate pro-inflammatory cytokine and chemokine production in macrophages. In preliminary studies, we evaluated selected pro-inflammatory cytokine and chemokine levels, including MCP-1 and the central pro-inflammatory cytokine IL-12, in thioglycolate-induced peritoneal macrophages, using quantitative RT-PCR. Monocyte chemoattractant 1 (MCP-1), which recruits macrophages and other hematopoietic lineages to sites of inflammation, was increased by 85% in NOD macrophages relative to those from NOD-*Alox15*<sup>null</sup> mice. Similarly, IL-12p40 was highly expressed in NOD macrophages but virtually undetectable in the knockout strain, suggesting that both macrophage migration and activation were likely to be defective in these mice (N.A.M., unpublished observations).

Once insulinitis has been established in NOD mice, several lines of evidence suggest that  $\beta$ -cell damage leading to insulin deficiency occurs in parallel with decreases in the number and/or function of Foxp3<sup>+</sup> regulatory T cells (reviewed in (46)). Although we found that CD4<sup>+</sup> T cells are strikingly decreased in the pancreas of NOD-*Alox15*<sup>null</sup> mice, these mice exhibit increased numbers of Foxp3<sup>+</sup> cells in the peri-islet infiltrates. This observation suggests that the absence of 12/15-LO activity may allow enhanced production and recruitment of regulatory T cells to the pancreas while limiting the recruitment of potential effector cells. In ongoing studies, we are investigating the possibility that enhanced regulatory cell activity can be linked to altered macrophage function in these congenic mice.

The pathways regulating 12/15-LO expression in islets or macrophages are complex and incompletely characterized. As previously noted, increased 12/15-LO activity enhances production of IL-12 in macrophages (15), consistent with a predominantly Th1-type activity associated with disease in NOD mice. Interleukin 4 (IL-4), a T-cell-derived cytokine, is commonly associated with Th2 or protective responses in autoimmunity through its suppressive action on antigen presenting cells such as B lymphocytes or macrophages. However, IL-4 has been shown to increase 12/15-LO expression in mice (47). Taken together with the protective effects of deleting 12/15-LO in our study, this poses a potential conundrum. However, the link between IL-4 responses and pro-inflammatory IL-12 production through 12/15-LO is consistent with the observation that transgenic NOD mice expressing high levels of IL-4 under the control of the rat insulin promoter actually show increased inflammation and enhancement of islet-specific effector T cell function (48). IL-4 does appear to decrease the severity of experimental allergic encephalomyelitis (EAE), a rodent model of multiple sclerosis (49), possibly accounting for the report that deletion of 12/15-LO exacerbates EAE in mice (50). We speculate that the protective action of 12/15-LO in the NOD mouse model of type 1 diabetes is due to the important role of IL-12 in Type 1 diabetes, in contrast to the critical role of IL-23 (and not IL-12) for the induction of EAE (51). Whether 12/15-LO activity in pancreatic  $\beta$ -cells also contributes to the development of insulinitis and diabetes remains to be determined (52,53)

In summary, data from the NOD-*Alox15*<sup>null</sup> mouse suggests an important role for 12/15-LO in conferring susceptibility to autoimmune diabetes in NOD mice. The demonstration that islet-associated activated macrophages are markedly decreased in NOD-*Alox15*<sup>null</sup> mice prior to the onset of significant infiltration by T lymphocytes strongly suggests that 12/15-LO, or one of its products, is essential for disease initiation through its pro-inflammatory effects on macrophages, perhaps leading to decreased recruitment and/or survival of Foxp3<sup>+</sup> regulatory cells. Whether or not the human homologue can be shown to play a role in disease susceptibility, we postulate that pharmacological blockade of

either 12/15-LO activity or signaling downstream of a 12/15-LO-derived lipid mediator could provide a new approach to protecting  $\beta$ -cells from immune injury through alterations in the selective recruitment of regulatory vs. effector cells. There are currently no compounds available for testing *in vivo* that specifically inhibit 12/15-LO and have a favorable long-term toxicity profile (54,55). However the data proposed in this study would suggest a possible clinical role for

a specific and safe 12/15-LO inhibitor for use in clinical trials.

#### **ACKNOWLEDGMENTS**

This work was supported by the following grants: NIH RO1 DK55240; DERC and Animal Characterization Core and Cell and Islet Isolation Core Facilities at UVA DK063609; Institutional Diabetes Training Grant DK007320-29. Data presented in abstract form at the 67<sup>th</sup> American Diabetes Association Scientific Sessions in 2007.

REFERENCES

1. Atkinson MA, Leiter EH: The NOD mouse model of type 1 diabetes: as good as it gets? *Nat Med* 5:601-604, 1999
2. Maier LM, Wicker LS: Genetic susceptibility to type 1 diabetes. *Curr Opin Immunol* 17:601-608, 2005
3. Todd JA, Aitman TJ, Cornall RJ, Ghosh S, Hall JR, Hearne CM, Knight AM, Love JM, McAleer MA, Prins JB, .: Genetic analysis of autoimmune type 1 diabetes mellitus in mice. *Nature* 351:542-547, 1991
4. Ivakine EA, Fox CJ, Paterson AD, Mortin-Toth SM, Canty A, Walton DS, Aleksa K, Ito S, Danska JS: Sex-specific effect of insulin-dependent diabetes 4 on regulation of diabetes pathogenesis in the nonobese diabetic mouse. *J Immunol* 174:7129-7140, 2005
5. McDuffie M: Derivation of diabetes-resistant congenic lines from the nonobese diabetic mouse. *Clin Immunol* 96:119-130, 2000
6. Litherland SA, Grebe KM, Belkin NS, Paek E, Elf J, Atkinson M, Morel L, Clare-Salzler MJ, McDuffie M: Nonobese diabetic mouse congenic analysis reveals chromosome 11 locus contributing to diabetes susceptibility, macrophage STAT5 dysfunction, and granulocyte-macrophage colony-stimulating factor overproduction. *J Immunol* 175:4561-4565, 2005
7. Grattan M, Mi QS, Meagher C, Delovitch TL: Congenic mapping of the diabetogenic locus *Idd4* to a 5.2-cM region of chromosome 11 in NOD mice: identification of two potential candidate subloci. *Diabetes* 51:215-223, 2002
8. Ivakine EA, Mortin-Toth SM, Gulban OM, Valova A, Canty A, Scott C, Danska JS: The *idd4* locus displays sex-specific epistatic effects on type 1 diabetes susceptibility in nonobese diabetic mice. *Diabetes* 55:3611-3619, 2006
9. Davoodi-Semiromi A, Laloraya M, Kumar GP, Purohit S, Jha RK, She JX: A mutant *Stat5b* with weaker DNA binding affinity defines a key defective pathway in nonobese diabetic mice. *J Biol Chem* 279:11553-11561, 2004
10. Laloraya M, Davoodi-Semiromi A, Kumar GP, McDuffie M, She JX: Impaired *Crkl* expression contributes to the defective DNA binding of *Stat5b* in nonobese diabetic mice. *Diabetes* 55:734-741, 2006
11. Ymer SI, Huang D, Penna G, Gregori S, Branson K, Adorini L, Morahan G: Polymorphisms in the *Il12b* gene affect structure and expression of IL-12 in NOD and other autoimmune-prone mouse strains. *Genes Immun* 3:151-157, 2002
12. Chen XS, Kurre U, Jenkins NA, Copeland NG, Funk CD: cDNA cloning, expression, mutagenesis of C-terminal isoleucine, genomic structure, and chromosomal localizations of murine 12-lipoxygenases. *J Biol Chem* 269:13979-13987, 1994
13. Chen M, Yang ZD, Smith KM, Carter JD, Nadler JL: Activation of 12-lipoxygenase in proinflammatory cytokine-mediated beta cell toxicity. *Diabetologia* 48:486-495, 2005
14. Soberman RJ, Harper TW, Betteridge D, Lewis RA, Austen KF: Characterization and separation of the arachidonic acid 5-lipoxygenase and linoleic acid omega-6 lipoxygenase (arachidonic acid 15-lipoxygenase) of human polymorphonuclear leukocytes. *J Biol Chem* 260:4508-4515, 1985
15. Yamamoto S, Nishimura M, Connors MS, Stoltz RA, Falck JR, Chauhan K, Laniado-Schwartzman M: Oxidation and keto reduction of 12-hydroxy-5,8,10,14-eicosatetraenoic acids in bovine corneal epithelial microsomes. *Biochim Biophys Acta* 1210:217-225, 1994

16. Jarpe AJ, Hickman MR, Anderson JT, Winter WE, Peck AB: Flow cytometric enumeration of mononuclear cell populations infiltrating the islets of Langerhans in prediabetic NOD mice: development of a model of autoimmune insulinitis for type I diabetes. *Reg Immunol* 3:305-317, 1990
17. Reddy S, Liu W, Elliott RB: Distribution of pancreatic macrophages preceding and during early insulinitis in young NOD mice. *Pancreas* 8:602-608, 1993
18. Charre S, Rosmalen JG, Pelegri C, Alves V, Leenen PJ, Drexhage HA, Homo-Delarche F: Abnormalities in dendritic cell and macrophage accumulation in the pancreas of nonobese diabetic (NOD) mice during the early neonatal period. *Histol Histopathol* 17:393-401, 2002
19. Jansen A, Homo-Delarche F, Hooijkaas H, Leenen PJ, Dardenne M, Drexhage HA: Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulinitis and beta-cell destruction in NOD mice. *Diabetes* 43:667-675, 1994
20. Rosmalen JG, Homo-Delarche F, Durant S, Kap M, Leenen PJ, Drexhage HA: Islet abnormalities associated with an early influx of dendritic cells and macrophages in NOD and NODscid mice. *Lab Invest* 80:769-777, 2000
21. Rosmalen JG, Martin T, Dobbs C, Voerman JS, Drexhage HA, Haskins K, Leenen PJ: Subsets of macrophages and dendritic cells in nonobese diabetic mouse pancreatic inflammatory infiltrates: correlation with the development of diabetes. *Lab Invest* 80:23-30, 2000
22. Serreze DV, Gaedeke JW, Leiter EH: Hematopoietic stem-cell defects underlying abnormal macrophage development and maturation in NOD/Lt mice: defective regulation of cytokine receptors and protein kinase C. *Proc Natl Acad Sci U S A* 90:9625-9629, 1993
23. Langmuir PB, Bridgett MM, Bothwell AL, Crispe IN: Bone marrow abnormalities in the non-obese diabetic mouse. *Int Immunol* 5:169-177, 1993
24. Alleva DG, Pavlovich RP, Grant C, Kaser SB, Beller DI: Aberrant macrophage cytokine production is a conserved feature among autoimmune-prone mouse strains: elevated interleukin (IL)-12 and an imbalance in tumor necrosis factor- $\alpha$  and IL-10 define a unique cytokine profile in macrophages from young nonobese diabetic mice. *Diabetes* 49:1106-1115, 2000
25. Liu J, Beller DI: Distinct pathways for NF- $\kappa$ B regulation are associated with aberrant macrophage IL-12 production in lupus- and diabetes-prone mouse strains. *J Immunol* 170:4489-4496, 2003
26. Maree AF, Komba M, Dyck C, Labecki M, Finegood DT, Edelstein-Keshet L: Quantifying macrophage defects in type 1 diabetes. *J Theor Biol* 233:533-551, 2005
27. Nikolic T, Bunk M, Drexhage HA, Leenen PJ: Bone marrow precursors of nonobese diabetic mice develop into defective macrophage-like dendritic cells in vitro. *J Immunol* 173:4342-4351, 2004
28. Stoffels K, Overbergh L, Giulietti A, Kasran A, Bouillon R, Gysemans C, Mathieu C: NOD macrophages produce high levels of inflammatory cytokines upon encounter of apoptotic or necrotic cells. *J Autoimmun* 23:9-15, 2004
29. Nikolic T, Bouma G, Drexhage HA, Leenen PJ: Diabetes-prone NOD mice show an expanded subpopulation of mature circulating monocytes, which preferentially develop into macrophage-like cells in vitro. *J Leukoc Biol* 78:70-79, 2005
30. O'Brien BA, Geng X, Orteu CH, Huang Y, Ghoreishi M, Zhang Y, Bush JA, Li G, Finegood DT, Dutz JP: A deficiency in the in vivo clearance of apoptotic cells is a feature of the NOD mouse. *J Autoimmun* 26:104-115, 2006

31. Middleton MK, Rubinstein T, Pure E: Cellular and molecular mechanisms of the selective regulation of IL-12 production by 12/15-lipoxygenase. *J Immunol* 176:265-274, 2006
32. Bleich D, Chen S, Gu JL, Thomas L, Scott S, Gonzales N, Natarajan R, Nadler JL: Interleukin-1 beta regulates the expression of a leukocyte type of 12-lipoxygenase in rat islets and RIN m5F cells. *Endocrinology* 136:5736-5744, 1995
33. Ma Z, Ramanadham S, Corbett JA, Bohrer A, Gross RW, McDaniel ML, Turk J: Interleukin-1 enhances pancreatic islet arachidonic acid 12-lipoxygenase product generation by increasing substrate availability through a nitric oxide-dependent mechanism. *J Biol Chem* 271:1029-1042, 1996
34. Bleich D, Chen S, Wen Y, Nadler JL: The stress-activated c-Jun protein kinase (JNK) is stimulated by lipoxygenase pathway product 12-HETE in RIN m5F cells. *Biochem Biophys Res Commun* 230:448-451, 1997
35. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Funk CD: Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. *J Clin Invest* 103:1597-1604, 1999
36. Bleich D, Chen S, Zipser B, Sun D, Funk CD, Nadler JL: Resistance to type 1 diabetes induction in 12-lipoxygenase knockout mice. *J Clin Invest* 103:1431-1436, 1999
37. Sun D, Funk CD: Disruption of 12/15-lipoxygenase expression in peritoneal macrophages. Enhanced utilization of the 5-lipoxygenase pathway and diminished oxidation of low density lipoprotein. *J Biol Chem* 271:24055-24062, 1996
38. Dietrich WF, Miller J, Steen R, Merchant MA, Mron-Boles D, Husain Z, Dredge R, Daly MJ, Ingalls KA, O'Connor TJ: A comprehensive genetic map of the mouse genome. *Nature* 380:149-152, 1996
39. George J, Afek A, Shaish A, Levkovitz H, Bloom N, Cyrus T, Zhao L, Funk CD, Sigal E, Harats D: 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. *Circulation* 104:1646-1650, 2001
40. Reilly KB, Srinivasan S, Hatley ME, Patricia MK, Lannigan J, Bolick DT, Vandenhoff G, Pei H, Natarajan R, Nadler JL, Hedrick CC: 12/15-Lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo. *J Biol Chem* 279:9440-9450, 2004
41. Yang Z, Chen M, Ellett JD, Fialkow LB, Carter JD, McDuffie M, Nadler JL: Autoimmune diabetes is blocked in Stat4-deficient mice. *J Autoimmun* 22:191-200, 2004
42. Ivakine EA, Gulban OM, Mortin-Toth SM, Wankiewicz E, Scott C, Spurrell D, Canty A, Danska JS: Molecular genetic analysis of the Idd4 locus implicates the IFN response in type 1 diabetes susceptibility in nonobese diabetic mice. *J Immunol* 176:2976-2990, 2006
43. Razavi R, Chan Y, Afifiyan FN, Liu XJ, Wan X, Yantha J, Tsui H, Tang L, Tsai S, Santamaria P, Driver JP, Serreze D, Salter MW, Dosch HM: TRPV1+ sensory neurons control beta cell stress and islet inflammation in autoimmune diabetes. *Cell* 127:1123-1135, 2006
44. Bour-Jordan H, Bluestone JA: Sensory neurons link the nervous system and autoimmune diabetes. *Cell* 127:1097-1099, 2006
45. Leiter, E. H. The Jackson Laboratory. [http://www.jax.org/t1dr/images/5311\\_5312\\_5313\\_idd\\_sweep\\_and\\_chr1\\_and\\_11\\_s\\_can.jpg](http://www.jax.org/t1dr/images/5311_5312_5313_idd_sweep_and_chr1_and_11_s_can.jpg). 11-9-2006. 8-20-2007.
46. Bluestone JA, Tang Q: Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. *Proc Natl Acad Sci U S A* 101 Suppl 2:14622-14626, 2004

47. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, Witztum JL, Funk CD, Conrad D, Glass CK: Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. *Nature* 400:378-382, 1999
48. Falcone M, Yeung B, Tucker L, Rodriguez E, Krahl T, Sarvetnick N: IL-4 triggers autoimmune diabetes by increasing self-antigen presentation within the pancreatic islets. *Clin Immunol* 98:190-199, 2001
49. Ho SH, Lee HJ, Kim DS, Jeong JG, Kim S, Yu SS, Jin Z, Kim S, Kim JM: Intrasplenic electro-transfer of IL-4 encoding plasmid DNA efficiently inhibits rat experimental allergic encephalomyelitis. *Biochem Biophys Res Commun* 343:816-824, 2006
50. Emerson MR, LeVine SM: Experimental allergic encephalomyelitis is exacerbated in mice deficient for 12/15-lipoxygenase or 5-lipoxygenase. *Brain Res* 1021:140-145, 2004
51. Thakker P, Leach MW, Kuang W, Benoit SE, Leonard JP, Marusic S: IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. *J Immunol* 178:2589-2598, 2007
52. Bleich D, Chen S, Gu JL, Nadler JL: The role of 12-lipoxygenase in pancreatic - cells (Review). *Int J Mol Med* 1:265-272, 1998
53. Wen Y, Gu J, Chakrabarti SK, Aylor K, Marshall J, Takahashi Y, Yoshimoto T, Nadler JL: The role of 12/15-lipoxygenase in the expression of interleukin-6 and tumor necrosis factor-alpha in macrophages. *Endocrinology* 148:1313-1322, 2007
54. Im JY, Han PL: Nordihydroguaiaretic acid induces astroglial death via glutathione depletion. *J Neurosci Res* 2007
55. Fujimoto Y, Ikeda M, Sakuma S: Monochloramine potently inhibits arachidonic acid metabolism in rat platelets. *Biochem Biophys Res Commun* 344:140-145, 2006

**Table 1. Fasting Blood Glucose and Plasma Insulin in NOD and NOD-*Alox15*<sup>null</sup> Mice**

<b>Genotype</b>	<b><i>N</i></b>	<b>Blood glucose [mg/dL]</b>	<b>Insulin [ng/ml]</b>	<b>HOMA</b>
<b>NOD</b>	4	80 +/- 6	0.13 +/- 0.037	0.71 +/- 0.165
<b>NOD-<i>Alox15</i><sup>null</sup></b>	5	74 +/- 10	0.17 +/- 0.047	0.82 +/- 0.208
<b><i>P-value</i></b>		0.622	0.559	0.713



**Table 2. Insulinitis scores**

<b>Pancreatic histology</b>	<b>NOD</b>	<b>NOD-<i>Alox15</i><sup>null</sup></b>	<b><i>P</i>-value</b>
<b>Periductular infiltrate (range: 0-3)</b>	1.9 (±0.34)	0.8 (±0.19)	6.9 x 10 <sup>-3</sup>
<b>Insulitis (range: 0-3)</b>	2.6 (±0.14)	0.9 (±0.25)	0.2 x 10 <sup>-3</sup>
<b>Islet mass (range: 0-1)</b>	0.3 (±0.11)	0.8 (±0.09)	1.3 x 10 <sup>-3</sup>
<b>β-cell granulation (range: 0-100)</b>	31.1 (±12.2)	92.7 (±4.25)	0.2 x 10 <sup>-4</sup>
<b>Total score (mass x granulation)</b>	13.0 (±7.08)	72.5 (±9.42)	0.2 x 10 <sup>-3</sup>

## FIGURE LEGENDS

### Figure 1.

**A) Location of the fragment introgressed to generate the NOD-*Alox15*<sup>null</sup> congenic strain.** Black intervals represent confirmed homozygosity for B6;129S2 from the donor B6;129S2-*Alox15*<sup>tm1Fun</sup> strain; light gray intervals, indeterminate regions containing recombination endpoints for the congenic interval; white intervals, regions derived from the congenic background strain.

**B) Intervals defining sub-loci for *Idd4* in congenic mouse strains.**

I) map of NOD-*Alox15*<sup>null</sup> mice (this report); II) composite map from NOD-Idd4A and NOD-Idd4B (7), showing localization of *Idd4.1* and *Idd4.2*; III) composite map of NOD contributions to informative NOR.NOD-Idd4R3 and NOR.NOD-Idd4R3 congenic lines (42) and IV) map of NOD.Lc11b, showing localization of *Idd4.3* (6). Black intervals represent confirmed homozygosity for donor alleles: B6;129S2 in panel I, B6 in panel II, NOD in panel III; white intervals, regions derived from the congenic background strain; light gray intervals, indeterminate regions containing recombination endpoints. In panel III, dark gray intervals represent known NOD-derived regions in informative congenic lines.

**Figure 2 A-B. Disease incidence in NOD-*Alox15*<sup>null</sup> mice compared to NOD mice.**

A) Females, N=40; B) Males, N=34. Filled symbols: NOD-*Alox15*<sup>null</sup>; open symbols: NOD.

**Figure 2 C-D. Confirmation of 12/15-LO functional deletion.**

Comparison of expression of 12/15-LO in peritoneal exudate macrophages from NOD and NOD-*Alox15*<sup>null</sup> mice. C) Immunoblot D) Real-time quantitative RT-PCR

**Figure 3. Glucose Tolerance Test results for NOD and NOD-*Alox15*<sup>null</sup> mice**

Female NOD (black square, n = 5) and NOD-*Alox15*<sup>null</sup> (open triangle, n = 5) mice at 8 months of age were subjected to a glucose tolerance test. Data points represent mean blood glucose values +/- SE. Differences in blood glucose levels were statistically significant over the entire test period (p<0.0001 by two-way ANOVA).

**Figure 4. Aldehyde Fuchsin staining of the islets**

Fourteen non-diabetic female NOD-*Alox15*<sup>null</sup> mice and 10 non-diabetic NOD females were evaluated for insulinitis and beta cell granulation at 30 weeks of age. Pancreata were stained with aldehyde fuchsin and evaluated by standard light microscopy. **A.** Representative section showing a well preserved islet in a NOD-*Alox15*<sup>null</sup> mouse. **B.** A representative example of an infiltrated islet seen in an age-matched, non-diabetic NOD mouse.

**Figure 5. Immunofluorescent staining of frozen pancreatic sections from NOD and NOD-*Alox15*<sup>null</sup> islets.**

Representative sections from 9.5-week-old NOD (A) or NOD-*Alox15*<sup>null</sup> mice (B) and 30+-week-old NOD (C) or NOD-*Alox15*<sup>null</sup> mice (D) were stained with antibodies against insulin (red) and CD4 (green), as well as Hoechst dye (blue, nuclear staining). Panels E (NOD) and F (NOD-*Alox15*<sup>null</sup>) show representative sections from 30+-week-old mice co-stained for insulin (green), Foxp3 (red), and Hoechst (blue).

**Figure 6. Islet-associated activated macophages**

Pancreata from 4-week-old NOD (A) and NOD-*Alox15*<sup>null</sup> (B) mice were stained for Mac-2 (brown) and blindly scored for degree of infiltration. Sections shown are representative of the results from 4 individual mice from each strain.

FIGURE 1







FIGURE 2



C



D






FIGURE 3



**FIGURE 4**

**A**



**B**





FIGURE 5

**NOD islets**

**NOD-*Alox15*<sup>null</sup> islets**

**CD4 (green), insulin (red), DAPI (blue)**



**Foxp3 (red), insulin (green), DAPI (blue)**







FIGURE 6

**A. NOD islets at 4 weeks**



**B. NOD-*Alox15*<sup>null</sup> islets at 4 weeks postnatal**

